Health officials issue warnings as UK bakes in the first heat wave of 2025
LONDON — British health officials are warning people across the country to take precautions when out in the sun as the U.K. bakes under its first heat wave of the year.
Temperatures are expected to peak at 34 degrees Celsius (93 degrees Fahrenheit) in some parts of eastern England on Saturday following a week of unusually warm weather, according to the national weather agency the Met Office. That's about 12 C (22 F) higher than normal for this time of year.
The U.K. Health Security Agency has issued an amber heat health alert covering all of England because of increased health risks for people over 65 and those with heart and lung problems.
'Heat can result in serious health outcomes across the population, especially for older adults or those with pre-existing health conditions,' Dr. Agostinho Sousa, head of the UKHSA, said in a statement. 'It is therefore important to check on friends, family and neighbors who are more vulnerable and to take sensible precautions while enjoying the sun.'
Saturday is expected to be the hottest day of the heat wave, with temperatures falling slightly on Sunday and dropping back into the more normal temperatures next week, the Met Office said. The heat alert is currently scheduled to remain in effect until Monday morning.
Unusually, temperatures in London this week have been higher than in many parts of Western Europe. That's because the high temperatures are not the result of hot air moving north from the Iberian Peninsula or North Africa as is often the case, the Met Office said. Instead, this weather system originated in air high over the Atlantic Ocean south of Greenland. As it approaches the U.K., it descends toward ground level, causing it to warm rapidly, Chief Meteorologist Matthew Lenhert said.
That said, it has been plenty hot in Europe too. Aviation enthusiasts attending the Paris Air Show in Le Bourget, north of Paris, this week sought the shade of a Boeing 777's wing, cooling off as temperatures hovered in the low 30s C (mid-80s F.)
Met Office scientists this week published research showing that climate change is increasing the likelihood of extreme high temperatures in the U.K. The chance of temperatures exceeding 40 Celsius (104 F) is now more than 20 times higher than it was in the 1960s, the researchers said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Health Line
38 minutes ago
- Health Line
GLP-1 Weight Loss Results Not as Effective in Everyday Life, Study Finds
Researchers report that people taking GLP-1 drugs in daily life don't lose as much weight as those in clinical trials who take the same medications. The researchers add that people using weight loss drugs don't regain weight as quickly as those in clinical trials. One possible reason for the weight loss differential is that people in the 'real world' tend to stop taking these medications sooner than people in clinical trials. People who use commonly prescribed weight loss medications don't lose as much weight as participants in clinical trials, but they also don't regain weight as quickly. That's the conclusion of a new study published on June 10 in the journal Obesity. The study authors reported that the weight loss differential was mainly due to the fact that people tend to stop using GLP-1 drugs sooner than clinical trial participants. They also tend to use lower doses of these medications. The researchers also reported that A1C blood level reductions were similar for both groups of people. The researchers noted that they will initiate further research into what other measures, such as lifestyle changes or bariatric surgery, people may have adopted after discontinuing weight loss medications such as Wegovy and Zepbound. The researchers also want to look into why people stopped using weight loss drugs before their program regimen ended. 'Our findings indicate that treatment discontinuation and use of lower maintenance dosages might reduce the likelihood of achieving clinically meaningful weight reduction in patients who initiate obesity pharmacotherapy with semaglutide or tirzepatide,' the study authors wrote. 'Our findings could inform the decisions of healthcare providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight loss,' they added. 'Real world' use of weight loss medications For their study, researchers looked at the health records of 7,881 adults with obesity or weight management issues who did not have type 2 diabetes. Those people were seen between 2021 and 2023 at the Cleveland Clinic's facilities in Ohio and Florida. Their average age was about 51 years. Nearly 80% of the subjects were white. Of those participants, 6,109 were prescribed a weight loss medication such as Wegovy with the active ingredient semaglutide. The other 1,772 were prescribed a weight loss drug, such as Zepbound, with the active ingredient tirzepatide. About 80% of those subjects were given low doses of their weekly injectable weight loss medications. Researchers reported significant differences between people using weight loss medications in phase 3 clinical trials and those taking the drugs in the 'real world.' For starters, about half of those taking either medication in daily life stopped within the first 12 months. About 51% of those using a tirzepatide drug discontinued its use in that same time period. That compares with only 17% of semaglutide users and between 14% and 16% of tirzepatide users in clinical trials who quit during the first year. In addition, the average weight reduction for semaglutide participants in daily life was nearly 8% after one year while it was 12% for people taking tirzepatide. By comparison, the average weight loss in clinical trials was nearly 15% for semaglutide subjects as well as 15% for people on low dose tirzepatide and 20% for those on a higher dose of that medication. In general, weight loss was greater in people who took weight loss medications for a longer period of time. In addition, about 54% of people who had prediabetes at the start of their treatment plan improved to healthier A1C levels after one year. Around 3% of those studied progressed to type 2 diabetes after 12 months. Weight loss is a long-term commitment Mir Ali, MD, a surgeon and bariatric surgeon as well as the medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in California, said the main takeaway from this study is that weight loss is a long-term commitment. Ali wasn't involved in the new study. 'The long-term use of medications is more effective than short-term use,' Ali told Healthline. 'The study confirms that obesity is a chronic condition like diabetes or hypertension.' Sarah Kim, MD, a professor of medicine at the University of California San Francisco, noted that discontinuing medication is common for people being treated for obesity and other conditions. Kim was likewise not involved in the new study. Kim added that adherence to medication schedules as well as diet and exercise programs isn't as easy in real life because people don't have the supervision and support a person gets during a clinical trial. 'Real life is different and results aren't always as spectacular as in clinical trials,' Kim told Healthline. Kim and Ali agreed that another reason people stop taking medications is that these drugs can be expensive, even if insurance is picking up part of the cost. There is also the fact that the side effects from these medications can be severe for some people. Plus, people in real life sometimes just get tired of the obligation of taking a pill or injecting themselves on a regular basis. Ali and Kim also noted that people need to realize that medications are only a tool to help them eat less. To lose weight and keep it off, a person needs to adopt lifestyle habits such as a healthy diet and regular exercise. 'The medications are not a short-term kickstart. They don't burn fat,' said Kim. 'The medications just help with the suppression of hunger.' 'The ultimate goal of the medications is to give people a tool to get them to a healthy weight,' Ali added. What to know about GLP-1 drug for weight loss Glucagon-like peptide-1 receptor agonists (GLP-1s) work by mimicking a hormone in the body that helps regulate blood sugar levels and reduces hunger pangs. One class of the newer GLP-1 medications uses the active ingredient semaglutide. They are sold under different brand names. Ozempic and Rybelsus have been approved to treat type 2 diabetes. Wegovy is approved for use in weight management. Semaglutide drugs are available as both oral tablets and injections. The other newer group uses the active ingredient tirzepatide. Mounjaro is approved to treat type 2 diabetes. Zepbound is approved for use in weight management. These medications are available only as injections. Previous studies have highlighted the effectiveness of these drugs on helping people lose weight. Past research has also indicated that these weight loss drugs can help lower a person's risk of cancer as well as provide benefits to heart health and brain health. Experts say the medications have proven to be effective and their use is likely to increase. 'This is a massive market and it's not going to go away,' Ali said. 'These medications are going to continue to be a big part of weight loss programs.'
Medscape
39 minutes ago
- Medscape
Europe Recommends Stem Cell Therapy for Blood Cancers
At its June 2025 meeting, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) gave a recommendation for conditional marketing authorization in the European Union for Zemcelpro (dorocubicel/allogeneic umbilical cord-derived CD34- cells non-expanded, Cordex Biologics International Limited) to treat adults with hematologic malignancies. A conditional marketing authorization is granted to a medicinal product that fulfils an unmet medical need when the benefit to public health of immediate availability outweighs the risk inherent in the fact that additional data are still required. Hematologic malignancies include leukemias, lymphomas, myelodysplastic syndrome, and myelomas. The only potential curative treatment option for several of these cancers is allogeneic hematopoietic stem cell transplantation (allo-HSCT). This type of transplant involves using donated stem cells to replace the recipient's bone marrow cells to form new bone marrow that produces healthy blood cells. Zemcelpro can be used in patients requiring an allo-HSCT following myeloablative conditioning — chemotherapy and/or radiotherapy — for whom no other type of suitable donor cells is available, the agency said. Novel Cell Therapy Zemcelpro is a novel cell therapy containing expanded CD34+ cells (dorocubicel) and unexpanded CD34- cells, each derived from the same cord blood unit. By increasing the number of cells, Zemcelpro makes the stem cells from a small cord blood unit more effective. The benefit of Zemcelpro is its ability to induce neutrophil and platelet engraftment, as observed in two single-arm, open-label, phase 2 clinical studies. The decision by the CHMP was largely based on a pooled analysis of these studies, which included 25 patients. In total, 84% of patients achieved neutrophil engraftment within a median time of 20 days, and 68% of patients achieved platelet engraftment within a median time of 40 days. In its overall assessment of the available data, the Committee for Advanced Therapies (CAT), EMA's expert committee for cell- and gene-based medicines, found that the benefits of Zemcelpro outweighed the possible risks in patients with hematologic malignancies requiring allo-HSCT for whom no matched donor cells were available. Further Study Results Requested Zemcelpro will be available as a ≥ 0.23 x 106 viable CD34+ cells/mL / ≥ 0.53 x 106 viable CD3+ cells/mL dispersion for infusion. The most common side effects with the treatment include lymphopenia, infections, anemia, neutropenia, thrombocytopenia, leukopenia, hypogammaglobulinemia, febrile neutropenia, hypertension, engraftment syndrome, pneumonia, and graft-vs-host disease (GvHD). Zemcelpro was supported through EMA's Priority Medicines (PRIME) scheme, which provides early and enhanced scientific and regulatory support to medicines that have a particular potential to address patients' unmet medical needs. To confirm the safety and efficacy of the treatment, the company has been requested to submit long-term follow-up results of the single-arm studies, and conduct a randomized controlled study as well as a study based on a patient registry.
CBS News
41 minutes ago
- CBS News
Extreme heat watch issued for Southeast Michigan Saturday through Tuesday
An extreme heat watch has been issued for all of Southeast Michigan Saturday morning through Tuesday evening. Expect high temperatures well into the 90s and heat index temperatures at or above 100 degrees during daytime hours. Nights will be warm and muggy as overnight lows are expected to remain in the mid-70s through the stretch. NEXT Weather/CBS Detroit There may be showers to contend with on Saturday morning, but southwest winds gusting to around 25 to 30 mph will help clear out the clouds and usher in warm, moist air with afternoon temperatures reaching into the low 90s. NEXT Weather/CBS Detroit Near-record, or record-breaking, temperatures on Sunday and Monday will reach into the mid to upper 90s with little chance of cloud cover to provide relief. NEXT Weather/CBS Detroit NEXT Weather/CBS Detroit A cold front brings a chance of showers and storms in the middle of next week, with high temperatures in the mid-to-upper 80s through the end of next weekend.
